Faeth Therapeutics, Inc. Payments for Repurchase of Common Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- Faeth Therapeutics, Inc. payments for repurchase of common stock for the quarter ending 2023-12-31 was $252.00K.
- Faeth Therapeutics, Inc. payments for repurchase of common stock for the quarter ending 2023-09-30 was $2.34M.
- Faeth Therapeutics, Inc. payments for repurchase of common stock for fiscal 2023 was $10.38M.
| Period end | Payments for Repurchase of Common Stock 3 month | Payments for Repurchase of Common Stock 12 month |
|---|---|---|
| 2023-12-31 | $252.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $10.38M 10-K · filed 2025-03-28 |
| 2023-09-30 | $2.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |